Loading news...
IART faces macro headwinds and tight liquidity, but strong demand in its Codman Specialty Surgical unit and expanding international launches could support growth.
IART tops Q4 EPS and revenue estimates despite margin pressure and a sales dip, as shares edge higher and 2026 guidance signals modest growth.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.97 per share a year ago.
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025.
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company.
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART - Get Free Report) have been given a consensus rating of "Reduce" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy
Access Investment Management LLC reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ: IART) by 14.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 372,450 shares of the life sciences company's stock after selling 63,420 shares during the period.
Hussman Strategic Advisors Inc. purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 168,000 shares of the life sciences company's stock, valued at approximately $2,407,000. Hussman Strategic Advisors Inc. owned
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART - Get Free Report) have earned an average rating of "Reduce" from the seven research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT
Assenagon Asset Management S.A. lessened its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) by 62.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 454,352 shares of the life sciences company's stock after selling
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules.